Universitè De Montpellier

Institut National De La Sante Et De La Recherche Medicale

Institut Regional Du Cancer De Montpellier

Inserm (institut National De La Sante Et De La Recherche Medicale)

Oribase Pharma

Institut Regional Du Cancer De Montpellier-val D'aurelle

Centre National De La Recherche Scientifique

Commissariat &#xc0; L'&#xc9;nergie Atomique Et Aux &#xc9;nergies Alternatives

Sorbonne Université

Université Paris Diderot-Paris 7

Centre National De La Recherche Scientifique-cnrs

UniversitÉ De Paris

Université De Lille

Institut Pasteur De Lille

Metafora Biosystems

Bruno Robert

Pierre Martineau

Myriam Chentouf

Christel Larbouret

Andre Pelegrin

Thierry Chardes

Armand Bensussan

André Pelegrin

Marc Sitbon

Vincent Petit

Bénédicte Fauvel

Jean-Luc Battini

Christian Larroque

Gwenael Cheve

Aziz Yasri

Wilhem Leconet

Philippe Gosset

Muriel Pichavant

Alain Couvineau

Thierry Voisin

Marie-Alix Poul

Nathalie Di Clemente-Besse

Pascal Nicole

Donatella Giovannini

Mélina Le Roux

Maëva Chauvin

Rienk Van Grondelle

Dmitrij Frolov

Andrew Gall

Guangqi E

Jérôme Giustiniani

Anne Marie-Cardine

Jawida Touhami

Muriel Busson

Samuel Sevestre

Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality worldwide. Acute exacerbation of COPD (AE-COPD) in patients are mostly due to respiratory infection and are associated with an inexorable decline in lung function, enhanced oedema as well as airway and systemic inflammation. Previous results show that treatment with anti-IL-20Rb blocking antibodies increased the bacterial clearance in control mice infected byand protected CS-exposed mice from bacterial infection, by decreasing the bacterial burden and the inflammatory infiltrate. Therefore there is an interest for generating monoclonal antibodies specific for IL-20Rb with a neutralizing activity for their use in the treatment of AE-COPD. The present invention fulfills this need by providing antibodies having specificity for IL-20Rb.

Monoclonal antibodies specific for IL20-Rb, encoding nucleic acids thereof and methods of use thereof to treat bacterial-induced exacerbation of chronic obstructive pulmonary disease

In ovarian carcinoma, Müllerian Inhibiting Substance (MIS) type II receptor (MISRII) and the MIS/MISRII signaling pathway are potential therapeutic targets. Conversely, the role of the three MIS type I receptors (MISRI; ALK2, ALK3 and ALK6) in this cancer needs to be clarified. Using four ovarian cancer cell lines and ovarian cancer cells isolated from patients' tumor ascites, the inventors found that ALK2 and ALK3 are the two main MISRIs involved in MIS signaling at low and high MIS concentrations, respectively. Moreover, high MIS concentrations were associated with apoptosis and decreased clonogenic survival, whereas low MIS concentrations improved cancer cell viability. Finally, the inventors showed that anti-MIS antibody B10 inhibited MIS pro-survival effect. These last results open the way to an innovative therapeutic approach to suppress MIS proliferative effect, instead of administering high doses of MIS to induce cancer cell apoptosis.

Anti-müllerian inhibiting substance antibodies and uses thereof

The present invention relates to monoclonal antibodies that bind to the CD160-TM isoform. The inventors developed new monoclonal antibodies which bind to the CD160-TM isoform but dot not bind to the CD160 GPI-anchored isoform not to the CD160 soluble isoform. In particular, the antibodies of the present invention are suitable for amplifying NK cell activation and therefore cytotoxic functions NK cells.

Monoclonal antibodies binding to the CD160 transmembrane isoform

The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.

Human monoclonal antibodies against orexin receptor type 1

Method for obtaining an super-resolution image () of an object (), based upon an optical microscope () including a support plate () for bearing the object, an illumination source () for focusing an illumination beam () onto a target region of the support plate, a digital camera () including a matrix of sensors, comprising: capturing, by the digital camera, a first image of the target region; extracting, from the first image, a first block of pixel values provided by a sub-matrix (B) of the matrix of sensors; displacing, by a sub-diffraction limited distance, the support plate by the displacement block along a displacement axis; capturing, by the digital camera, a second image of the target region; extracting, from the second image, a second block of pixel values provided by the sub-matrix (B) of the matrix of sensors; storing said first and second blocks of pixel values as a first and second blocks of pixel values to be placed right next each other in the super-resolution image along the image axis (X, Y) corresponding to the displacement axis.

Imaging method, and system, for obtaining a super-resolution image of an object

The present disclosure provides human monoclonal antibodies and antibody-drug conjugates against AXL and their use for the treatment of cancer.

Human monoclonal antibodies against AXL

The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9 and SEQ ID NO: 10.

Anti-Axl antibodies and uses thereof

The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.

Growing community of inventors

Montpellier, France

Bruno Robert